Compass Pathways (CMPS) said Wednesday the US Food and Drug Administration accepted the investigational new drug application for COMP360 as a potential treatment of post-traumatic stress disorder, or PTSD.
The move allows the company to proceed with a phase 2b/3 trial in patients with PTSD.
Compass Pathways also said it amended its current term loan facility with Hercules Capital (HTGC), increasing the facility to up to $150 million and helping the company maintain cash into 2027.
Compass Pathways shares were up 5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments